Aizen is an AI-native biotechnology company pioneering oral peptides to transform the lives of patients and families burdened by chronic immune disorders. Powered by DaX—a foundational AI platform developed by Caltech faculty—we design de novo peptides that transcend natural biology through the expansive chemical landscape of non-canonical amino acids (ncAA).

Headquartered in San Diego and venture-backed, Aizen is advancing a proprietary pipeline of gut-restricted and systemic oral biologics. Simultaneously, we collaborate with global biopharma to deploy our platform against high-value technical frontiers, synthesizing the precision of antibodies with the stability and oral delivery of small molecules.